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Introduction
There is general consensus on the criteria for eval-
uating the equivalence of the extent of absorption 
in two drug products which exhibit simple linear 
kinetics, following their single administration to 
individuals [1]. In contrast, there is no agreement 
on testing parameters for absorption rates. Major 
regulatory agencies apply different criteria. For ex-
ample, the US Food and Drug Administration has 
identical expectations for judging the equivalence 
of two Cmax values (maximum plasma concentra-
tion) and two AUC values (area under the curve 
contrasting plasma concentration with time). The 
European Community considers that Cmax has 
generally larger variability than AUC and allows a 
more relaxed criterion to the former. The Canadi-
an Health Protection Branch requires, in view of 
the prevailing uncertainty about the variability of 
Cmax, that only the ratio of AUC values, recorded 
for the two formulations, should be between pre-
set limits [2-5].
A source of uncertainties is that Cmax is only an 
indirect measure of absorption rates and absorp-
tion rate constants, as are other indices. Thus, 
these metrics may have limited specificity, sensi-
tivity and precision. Explorations have been con-
ducted for an appropriate metric testing the equiv-
alence of absorption rates. For example, Endrenyi 
et al. [6,7] suggested that Cmax/AUC should be 
used as an indirect index of absorption rates and 
proposed regulatory criteria based on the comput-
ed variability of Cmax/AUC and Cmax. Bois et al. 
[8] and Reppas et al. [9] compared several indices 
under various modeling assumptions but have not 
reached decisive conclusions. Studies of the effec-
tive evaluation of bioequivalence have considered 
mostly the single administration of drugs which 
follow uncomplicated linear kinetics. Information 
on the quantitative features of procedures and in-
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Abstract
Aims: In order to ensure the therapeutic equivalence of generic products, it would be important to contrast measures additional to 
Cmax in order to assess differences in absorption rates.  Our aim was to compare partial AUC (PAUC), Swing, and PTF to Cmax in 
terms of sensitivity, specificity and linearity under identical kinetic conditions.
Methods: Single-dose and multiple-dose concentration curves were generated assuming one-compartment models. Kinetic sensitivity 
curves were obtained by gradually changing the absorption rate constant and keeping all other parameters fixed.
Results: Ideally, a metric should reflect specifically the investigated kinetic feature (e.g., the rate of absorption), be linearly related to 
it, and should exhibit high kinetic sensitivity.  Cmax is related nonlinearly to the rate of absorption, is nonspecific to it (reflects also the 
extent of absorption as well as the rates of disposition processes), lacks kinetic sensitivity even following a single administration.  Com-
pared to Cmax, PAUC was always more sensitive under every investigated condition.  Swing and PTF showed high kinetic sensitivity 
but, in contrast to PAUC, they could be evaluated only in multiple-dose studies.  
Conclusion: Under identical conditions, different metrics provide widely differing point estimates.  Differences in kinetic sensitivity 
among bioequivalence metrics should be accounted for when results of different metrics are compared.
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dices for testing bioequivalence in the steady state 
is more limited.
Therefore, the present communication has two 
main goals: (1) To develop principles by which 
metrics characterizing pharmacokinetic features, 
especially those involving bioavailability and bio-
equivalence, can be evaluated; (2) to illustrate the 
application of the principles following single and 
repeated dose administration.
Useful Features of Metrics Characterizing 
Bioavailahility and Bioequivalence
Studies were performed [8-10] which recorded dif-
ficulties and complications in evaluating indirect 
metrics which characterize absorption rates, and 
evaluated their comparisons. Therefore, criteria 
for assessing features of such metrics will be dis-
cussed.
An ideal metric used for the evaluation of bio-
availability and bioequivalence should reflect spe-
cifically the underlying kinetic parameter, be re-
lated linearly to it, have high kinetic sensitivity, 
and exhibit high statistical insensitivity. Direct 
metrics possess these features; the performance of 
AUC reflecting the extent of drug absorption 
serves as an example. Cmax is an indirect metric 
for the rate of absorption; its general characteris-
tics and some of the difficulties noted after the sin-
gle administration of drug products will be illus-
trated in this section.
Specificity
A good metric should represent solely, specifically 
the investigated kinetic feature. For example, AUC 
is specific since it reflects only, in conjunction, 
plasma clearance and the extent of absorption; it 
does not depend on other kinetic parameters. In 
contrast, Cmax reflects nonspecifically the rate of 
absorption; it depends also on the rates of disposi-
tion processes as well as the extent of absorption. 
Cmax/AUC is more specific than Cmax since it 
does not reflect the extent of absorption [6]. How-
ever, this parameter still varies along with the 
rates of disposition processes.
Linearity
The relationship between the applied metric and 
the investigated kinetic feature is characterized by 
a mathematical relationship. In the simplest case, 
the relationship is linear. For example, the mea-
sured AUC depends linearly on the extent of ab-
sorption. On the other hand, AUC is related recip-
rocally to plasma clearance. Consequently, the 
logarithm of AUC is connected linearly to the log-
arithms of both the extent of absorption and plas-
ma clearance.
In contrast, Cmax is related nonlinearly to ka 
(the absorption rate constant). As discussed in the 
next subsection, the lack of kinetic sensitivity is a 
consequence of nonlinearity. Moreover, the ob-
served variation of nonlinear metrics depends not 
only on the intraindividual but also intersubject 
variability of the underlying parameter(s). In ad-
dition, criteria for corresponding, parallel regula-
tory conditions depend on the levels of the sourc-
es of variation.
Kinetic Sensitivity
If a change in an investigated kinetic parameter 
elicits an identical change in the measured metric, 
then the latter can be said to exhibit full kinetic 
sensitivity. Full kinetic sensitivity prevails with 
respect to the extent of absorption: a 25% change 
in the latter elicits a 25% change in AUC. If, how-
ever, a change in the parameter gives rise to a 
much smaller change in the metric then, the met-
ric lacks full kinetic sensitivity to the parameter. 
Kinetic sensitivity can be evaluated, approxi-
mately, from the slopes of relationships between 
the metrics and the investigated parameters. Use 
of a double-logarithmic relationship is convenient 
since both kinetic metrics and parameters have 
multiplicative character. 
However, studies of the effective evaluation of 
bioequivalence have usually considered single-
dose administration scenarios for drugs with un-
complicated linear kinetics. There are substantial-
ly fewer studies in the steady state. Even though it 
is generally recognized that Cmax is an insensitive 
metric [6-9] much less is known about its behavior 
at steady state, and how Cmax sensitivity com-
pares to other steady-state metrics proposed in the 
literature. Furthermore, results obtained from sin-
gle-dose studies cannot be directly compared with 
the steady-state results unless the kinetic condi-
tions are identical. Partial AUC (PAUC) is a re-
cently introduced early exposure measure defined 
as the area under the curve until the time of maxi-
mum concentration (Tmax) of the reference for-
mulation [10]. Its kinetic properties have been in-
vestigated following single-dose administration 
but not under steady-state conditions. 
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Therefore, we set the goal 
to compare the kinetic sensi-
tivities of Cmax and the pro-
posed alternative metrics, in-
cluding PAUC, following sin-
gle and repeated dose admin-
istrations under identical con-
ditions. 
Methods
The kinetic model in the calcu-
lations and simulations as-
sumed single exponential 
terms for absorption and dis-
position. Consequently, the 
time (t) course of concentra-
tions (C) was described by the 
expression following single ad-
ministration:
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where F is the fraction of dose absorbed into the sys-
temic circulation, Vd is the apparent volume of dis-
tribution, T is the maintenance time interval, Cl is 
the drug clearance and ka is the absorption rate con-
stant. The condition of single drug administration is 
approached as T is increased.
The application of several metrics has been pro-
posed [9] for repeated administration bioequiva-
lence studies. They include the maximum and 
minimum concentration (Cmax and Cmin), and 
the peak-trough fluctuation (PTF) and Swing 
which are defined as: 
PTF = Cmax/Cmin 
Swing = (Cmax - Cmin)/Cmin 
where Cmax and Cmin are the maximum and 
minimum concentrations, respectively, during a 
dosing interval.
The true average parameters for the reference 
product, drug R, were arbitrarily set to ka = 1.39h-1, 
Vd = 1 L, Cl = 0.347 L/h, Dose = 400 (in arbitrary 
units).
The kinetic equations were evaluated using 
Matlab (ver 2017b, MathWorks, USA).
Results
Single-Dose Administration
Figure 1A shows concentration profiles of a refer-
ence (R) and a test (T) drug product which differ in 
their rate constants but not in their extents of ab-
sorption. For the quantitative comparison of the 
curves appropriate single-number characteristics 
are needed. These are called bioequivalence met-
rics. Figure 1A illustrates the definitions of two 
commonly used metrics, Cmax and PAUC. The fig-
ure shows in red the concentration profile for the 
reference product with the stated kinetic parame-
Figure 1 Metric definitions and metric sensitivity following a single oral dose. 
(A)  Concentration-time profiles of the Reference (R) product in red and two Test 
(T) formulations, in black, following a single dose.  Absorption rate constants are 
compared indirectly, by comparing numerical characteristics called bioequivalence 
metrics from the observed concentrations.  The left panel of the figure illustrates 
the two regulatorily accepted bioequivalence metrics for absorption rates: Cmax 
and PAUC (shaded area).  The bioequivalence decision is based on the statistical 
comparison of the appropriate metrics such as CmaxT versus CmaxR.  (B) Calculated 
kinetic sensitivity curves contrasting the metric ratio with the corresponding ka, 
absorption rate constant, ratios. 
Table I Sensitivity  of absorption metrics following a single 
dose administration. The sensitivity of a bioequivalence 
metric is defined as the slope of the curve contrasting 
logarithmic absorption rate constants and logarithmic metric 
ratios. Sensitivities were calculated in two different kinetic 
conditions, when the elimination rate is relative fast to that 
of absorption (ka/ke=4) and when it much slower (ka/ke = 12)
Metrics Sensitivity
ka/ke ratio = 4 ka/ke ratio = 16
Cmax 0.269 0.123
PAUC 0.498 0.358
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ters. The concentration of two 
simulated subjects are also 
shown in black whose absorp-
tion rate constants are differ-
ent from that of the reference 
formulation but who have the 
same extent of absorption, and 
therefore the same AUC.
As the absorption rate con-
stant of the test formulation 
gradually increases (or de-
creases) relative to the refer-
ence product so do the corre-
sponding metrics. The quanti-
tative relationships between 
absorption rate constants and 
the metrics with default kinet-
ic parameters are displayed in 
Figure 1B. The slope between 
the logarithmic metric and ka 
ratios can be used for numerical comparison. 
Slopes approximating 1.0 suggest satisfactory, 
high sensitivity while small values indicate low 
sensitivities. Table I shows that the slopes of Cmax 
and PAUC are below 1. Therefore, compared to 
AUC, Cmax is not a sensitive metric. Compared to 
Cmax, PAUC is a more sensitive measure. How-
ever, neither indirect metric is specific, the slopes 
depend on the ka/ke ratio (Table I).
Repeated Drug Administration
The kinetic parameters in Figure 2A are the same as 
in Figure 1A but now the concentration profiles rep-
resent the steady-state condition. Cmax and PAUC 
increase with rising absorption rate constant, rela-
tive to the reference product, while Cmin (the con-
centration just before the next dose) decreases. 
Therefore, for easy visual comparison for Cmin we 
computed the CminR/CminT ratio instead of CminT/
CminR. Figure 2B shows that, at steady state, Swing 
is the most sensitive parameter followed by PTF 
and PAUC. Compared to these metrics, Cmax and 
Cmin are much less sensitive (Table II). Just as in 
the case of single dose administration, all slopes 
are smaller than 1 and they decrease in parallel 
with ka/ke ratio. The slopes are higher in Table I 
than in the corresponding entries of Table II. 
Discussion 
We computed and compared kinetic sensitivities 
of absorption metrics following single and repeat-
ed dosing in two different kinetic conditions. Even 
though the numerical details were different, the 
relative ranking remained the same. PAUC was al-
ways more sensitive than Cmax and metrics esti-
mated from single dose studies were more sensi-
tive than their steady-state counterparts. Howev-
er, considerations for assessing comparative ab-
sorption rates are much more difficult and compli-
cated in the steady state than following the single 
administration of drugs. The decrease in sensitivi-
ty was expected since the estimations generally 
involve the determination of the maximum con-
centration or a quantity related to it. The net 
height of concentration peaks (the fluctuation of 
concentrations) is lower in steady state than fol-
lowing a single administration and they further 
decrease with increasing accumulation. Neverthe-
less, Swing and PTF at steady state were more sen-
sitive than the metrics applied following a single 
dose. Therefore, it is possible construct sensitive 
metrics that can be applied under steady-state 
Figure 2 Metric definitions and metric sensitivity following repeated dosing. 
(A) Concentration-time profiles of the Reference (R) and two Test (T) formulations in 
steady state.  The left panel shows three directly calculated metrics for the reference 
drugs: the maximum concentration (CmaxR): the minimum concentration (CminR), 
and the area until Tmax (PAUCR).  (B) Calculated kinetic sensitivity curves contrasting 
the metric ratio with the corresponding ka, absorption rate constant ratios.  PTF and 
Swing are two additional, derived metrics defined as Cmax/Cmin and (Cmax-Cmin)/
Cmin, respectively.
Table II Pharmacokinetic sensitivities of 5 metrics estimating 
absorption rates in the steady state.  Under both kinetic 
conditions the between dose interval (T) equals with the drug 
half-life.
Metrics Sensitivity
ka/ke ratio = 4 ka/ke ratio = 16
Cmax 0.213 0.079
Cmin 0.287 0.062
PTF 0.499 0.138
Swing 0.673  0.360
PAUC 0.307 0.122
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conditions. This is important because in certain 
cases bioequivalence should be demonstrated in 
the steady state possibly because single-dose stud-
ies cannot be performed at all. Additional multi-
ple-dose bioequivalence studies are needed for 
prolonged-release formulations [11]. Multiple- 
dose bioequivalence studies are also accepted if a 
single-dose study cannot be conducted in healthy 
volunteers due to tolerability reasons. Multiple-
dose bioequivalence studies are recommended 
with drugs with dose- and time-dependent kinet-
ics such as strong enzyme inductors. In the latter 
case, the sensitivity can be even higher at steady 
state compared to a single dosing [12]. The reason 
is that due the enhanced elimination rate the ka/
ke ratio is smaller and, as we showed, the kinetic 
sensitivity of the absorption metrics negatively 
correlates with the ka/ke ratio (Tables I and II). 
Conclusion
Under identical conditions different metrics pro-
vide differing point estimates. Differences in ki-
netic sensitivities among bioequivalence metrics 
should be accounted for when results of different 
metrics are compared. The kinetic analysis of bio-
equivalence metrics helps also not only to design 
new, sensitive metrics but also to identify clinical 
situations when the results of standard single-
dose bioequivalence studies cannot be easily ex-
trapolated to clinical settings.
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